Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 31 - 36 of 36 results.

You searched for : June 2020 to June 2021.

Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Ad ...

Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer Download the PDF version of Article September 14, 2020 Phase 2 study to...

Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSC ...

Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual Meeting    Download the PDF version of Article September...

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Derux ...

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer Download...

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for ...

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 Download the PDF version of Article July 27, 2020 ...

Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and ...

Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and Patritumab Deruxtecan Download the PDF version of Article July 22, 2020 Multi-year, multi-study...

Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer

Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer Download the PDF version of Article July 01, 2020 Phase 1 study now evaluating DS-1062, a TROP2...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...